Randomized trial · people
SS-31: less kidney hypoxia after renal artery stenting in pilot
Checked against the paper Randomized trialPublished by PepVault
The takeaway
In a small human pilot trial, SS-31 given during kidney artery stenting was linked to less kidney oxygen loss right after the procedure and better kidney blood flow and filtering 3 months later.
- Kind
- Randomized trial
- Studied in
- People
- Published
- 2017
- Journal
- Circ Cardiovasc Interv
What they tested
The team tested whether giving elamipretide (SS-31) around a kidney artery stenting procedure would improve kidney function, oxygen levels and blood flow in people with a narrowed kidney artery.
How the study was done
A randomized, placebo-controlled phase 2a pilot trial in patients with severe narrowing of a kidney artery from plaque buildup who were scheduled for angioplasty and stenting (PTRA). Patients got an intravenous infusion of elamipretide at 0.05 mg/kg per hour (6 patients) or placebo, a dummy infusion (8 patients), before and during the procedure, with kidney scans before and 3 months after.

What they found
One day after stenting, the share of the kidney with low oxygen (fractional hypoxia) went up 47% in the placebo group but went down 6% in the elamipretide group, and both returned to baseline by 3 months. Blood flow to the narrowed kidney rose from 202±29 to 262±115 mL/min at 3 months (P=0.04), and this rise was seen only in the elamipretide group. Over 3 months, systolic blood pressure fell and estimated glomerular filtration rate (eGFR, a measure of how well the kidneys filter) rose more with elamipretide (P=0.003) than with placebo (P=0.11).
What it doesn’t show
This was a very small pilot trial with 6 and 8 patients per group, so the results are early and need confirming in larger trials. Follow-up lasted only 3 months, and the drug was tested only around a single stenting procedure.
The paper
Saad et al. Phase 2a Clinical Trial of Mitochondrial Protection (Elamipretide) During Stent Revascularization in Patients With Atherosclerotic Renal Artery Stenosis. Circ Cardiovasc Interv. 2017.
The compound
More studies on SS-31
- SS-31 (elamipretide) eye drops missed main vision goal in LHON trialRandomized trial · people · 2024
- SS-31: wearable data grouped responders with 100% accuracyRandomized trial · people · 2023
- SS-31: no 12-week benefit, walk gains by 36 weeks open-labelRandomized trial · people · 2021
- SS-31 raised muscle ATP capacity after one dose in older adultsRandomized trial · people · 2021
- SS-31: walk distance rose with dose in 5-day MMPOWER trialRandomized trial · people · 2018
- SS-31 did not significantly cut infarct size in EMBRACE STEMIRandomized trial · people · 2016
- Every study on SS-31
Researched and drafted with AI, then checked claim by claim against the primary sources linked below by a separate review pass. Published by PepVault. Last reviewed . Spot an error? feedback@pepvault.app. How we research. This page reports one study; it is not medical advice.